BCMA CAR Lentivirus

Concentrated on BCMA, a factor that proves to be involved in the development of multiple myeloma, the BCMA CAR Lentivirus reflects our striving to offer effective treatment for this complicated disease.

Check the CAR-T Cell Preparation-Lentivirus Packaging Service

Order information

Description

BCMA CAR Lentivirus created by GeneMedi is a complex treatment method designed to address multiple myeloma, a fearsome cancer of plasma cells. Multiple myeloma is a disease whereby there is excessive growth of plasma cells in the bone marrow which results in different negative effects such as bone marrow loss of toxicity, anemia and renal failure. Western methods can send the disease into remission, but it is more often than not that the disease is incurable and tends to recur. This is where our BCMA CAR Lentivirus comes in handy because BCMA is predominantly found on the surface of Myeloma cells and is almost undetectable in any other human tissue save for plasma cells, which are the very cells that have been transformed into tumors in this case.

Lentiviral vector system that we established for BCMA CAR-T cells is primarily based on the selectivity of the immune system wherein T cells are programmed to recognize and kill the BCMA-positive cells. The CAR construct incorporated into our lentivirus contains an scFv specific for BCMA, a flexible hinge region, a transmemodal domain to anchor it to the cell membrane and signaling domains within the cytoplasm that triggers T-cell activation on antigen binding. This fine-tuned CAR is a consequence of a sensitive work and type, which involves research to determine the best option of antigen recognition that kills cancer cells effectively with minimal or no influence on other cells.

We also know that it is not CAR-T cells that single handedly fight multiple myeloma. The milieu in which MM cells reside in the bone marrow may be toxic for T cells in some ways. Thus, our research team is continuing to develop approaches on how to improve the function of BCMA CAR-T cells in this hostile environment: including the use of co-stimulatory domains which will increase the survival time of T cells post-infusion, together with cytokines that have the ability to modify the local environment to be more receptive to CAR-T cells.

When ordering GeneMedi’s BCMA CAR Lentivirus, the client does not only get a ready viral vector, but also in-depth support in preclinical development, manufacturing, and compliance issues. Working in tandem with our clinical research partners, we carefully plan and conduct trials which assess the safety and utility of BCMA CAR-T cells, so that in the future, multiple myeloma is better understood and its treatment more axial and enduring.